Topical Povidone-Iodine as an Adjunctive Treatment for Recalcitrant Chronic Rhinosinusitis

Year 2019, Volume: 2 Issue: 2, 45 - 50, 08.10.2019

Warren Mullings Rikesh Panchmatia Katrien Samoy Al-Rahim Habib Andrew Thamboo Rami Al-Salman Amin Javer

Abstract

Objective: Recalcitrant chronic rhinosinusitis (CRS) is a persistent inflammation of the sino-nasal mucosa despite appropriate medical therapy and sinus surgery. The aim of the present study was to demonstrate the effect of topical povidone-iodine (PVP-I) sinus rinses on modified Lund–Kennedy (MLK) endoscopic scores.

Material and Methods: Retrospective chart review of patients with recalcitrant CRS (n=69) previously prescribed 0.08% adjunctive PVP-I sino-nasal rinses to evaluate changes in MLK scores and in the 22-item Sino-Nasal Outcome Test (SNOT-22) and a prospective cohort study lasting 7 weeks (n=17) were used to investigate safety outcomes.

Results: Mean total MLK decreased by 2.01 points (p<0.05, n=69) and median MLK-discharge decreased by 1.50 points (p<0.05, n=69) retrospectively. When MLK-discharge improved, 71% also had a reduction in edema. When MLK-discharge did not change, 42% had a reduction in edema. The efficacy of PVP-I on total MLK score reduction was greatest by the first follow-up visit at a median of 46 days, with sustained benefit thereafter not limited by gender, baseline disease severity, CRS subtype, duration of PVP-I use, or by concurrent antibiotic or antifungal use. Subjective SNOT-22 scores significantly improved by a minimal clinically important difference factor of 2.9 (p=0.02, n=15). Median thyroid-stimulating hormone (TSH) levels changed non-significantly (p=0.1, n=15) within normal ranges prospectively. Median mucociliary clearance time changed non-significantly (p=0.53, n=17) within normal ranges.

Conclusion: Ancillary 0.08% PVP-I sino-nasal rinses appear to reduce the endoscopic signs of inflammation and patient-reported symptomatology, while minimally affecting thyroid and mucociliary function. A larger scale randomized controlled trial incorporating microbiology associations is required to corroborate these findings.

Keywords

Povidone-iodine , betadine , chronic rhinosinusitis , recalcitrant , biofilm , treatment

References

• Desrosiers M, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard J, et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. Allergy Asthma Clin Immunol 2011; 7: 1-38.
• Rudmik L, Soler ZM, Hopkins C, Schlosser RJ, Peters A, White AA, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Int Forum Allergy Rhinol 2016; 6: 557-67.
• Cohen M, Kofonow J, Nayak JV, Palmer JN, Chiu AG, Leid JG, et al. Biofilms in chronic rhinosinusitis: A review. Am J Rhinol Allergy 2009; 23: 255-60.
• Foreman A, Jervis-Bardy J, Wormald PJ. Do biofilms contribute to the initiation and recalcitrance of chronic rhinosinusitis? Laryngoscope 2011; 121: 1085-91.
• Ramakrishnan Y, Shields RC, ElBadawey MR, Wilson JA. Biofilms in chronic rhinosinusitis: What is new and where next? J Laryngol Otol 2015; 129: 744-51.
• Rudmik L, Hoy M, Schlosser RJ, Harvey RJ, Welch KC, Lund V, et al. Topical therapies in the management of chronic rhinosinusitis: An evidence-based review with recommendations. Int Forum Allergy Rhinol 2013; 3: 281-98.
• Varshney R, Lee JT. Current trends in topical therapies for chronic rhinosinusitis: update and literature review. Expert Opin Drug Deliv 2017; 14: 257-71.
• Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, Pyon JK, Wa CTC, Villa MA. Povidone iodine in wound healing: A review of current concepts and practices. Int J Surg 2017; 44: 260-8.
• Kanagalingam J, Feliciano R, Hah JH, Labib H, Le TA, Lin JC. Practical use of povidone-iodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections. Int J Clin Pract 2015; 69: 1247-56
• Gan EC, Javer AR. Fungal Rhinosinusitis. In: Watkinson JC, Clarke RW, eds. Scott-Brown’s Otorhinolaryngology and Head and Neck Surgery. 8th ed. London: Hodder Arnold, 2018.
• Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol 2009; 34: 447-54.
• Hopkins C, Slack R, Lund V, Brown P, Copley L, Browne J. Long-term outcomes from the english national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Laryngoscope 2009; 119: 2459-65.
• Lind H, Joergensen G, Lange B, Svendstrup F, Kjeldsen AD. Efficacy of ESS in chronic rhinosinusitis with and without nasal polyposis: a Danish cohort study. Eur Arch Otorhinolaryngol 2016; 273: 911-9.
• Berkelman Rl, Holland Bw, Anderson Rl. Increased Bactericidal Activity of Dilute Preparations of Povidone-Jodine Solutions. J Clin Microbiol 1982; 15: 5.
• Reimer K, Wichelhaus TA, Schäfer V, Rudolph P, Kramer A, Wutzler P, et al. Antimicrobial Effectiveness of Povidone-Iodine and Consequences for New Application Areas. Dermatology. 2002; 204: 114-20.
• Psaltis AJ, Li G, Vaezeafshar R, Cho KS, Hwang PH. Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures. Laryngoscope 2014; 124: 2216-23.
• Deborah S, Km P. Clinical Research in Pulmonology Measurement of Nasal Mucociliary Clearance. Clin Res Pulmonol 2014; 2: 2-5.
• Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? BMJ 2009; 338: 1317-20.
• Casado AF, Lachapelle J-M, Tennstedt D, Lambert J, Leroy B, Micali G, et al. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clin Pract 2013; 10: 579-92.
• Hoekstra MJ, Westgate SJ, Mueller S. Povidone-iodine ointment demonstrates in vitro efficacy against biofilm formation. Int Wound J 2017; 14: 172-9.
• Percival SL, Finnegan S, Donelli G, Vuotto C, Rimmer S, Lipsky BA. Antiseptics for treating infected wounds: Efficacy on biofilms and effect of pH. Crit Rev Microbiol 2016; 42: 293-309.
• Isenberg SJ, Apt L, Valenton M, Sharma S, Gard P, Thomas PA, et al. Prospective, Randomized Clinical Trial of Povidone-Iodine 1.25% Solution Versus Topical Antibiotics for Treatment of Bacterial Keratitis. Am J Ophthalmol 2017; 176: 244-53.
• Arakeri G, Brennan PA. Povidone-iodine: an anti-oedematous agent? Int J Oral Maxillofac Surg 2011; 40: 173-6.
• Kim JH, Rimmer J, Mrad N, Ahmadzada S, Harvey RJ. Betadine has a ciliotoxic effect on ciliated human respiratory cells. J Laryngol Otol 2015; 129: 45-50.
• Sibbald R, Leaper D, Queen D. Iodine made easy. Wounds Int 2011; 2:1-6.
• Tan NC, Foreman A, Jardeleza C, Douglas R, Vreugde S, Wormald PJ. Intracellular Staphylococcus aureus: The Trojan horse of recalcitrant chronic rhinosinusitis? Int Forum Allergy Rhinol 2013; 3: 261-6.
• Lachapelle JM. A comparison of the irritant and allergenic properties of antiseptics. Eur J Dermatol 2014; 24: 3-9.
• Woo KY. Management of non-healable or maintenance wounds with topical povidone iodine. Int Wound J 2014; 11: 622-6.